Apimeds Pharmaceuticals Us, INC

Apimeds Pharmaceuticals US, Inc. has appointed Dr. Christopher Kim as Chief Scientific Officer to lead the development of its APITOX program.

Apimeds Pharmaceuticals US, Inc. announced a revised effective date for its previously approved 1-for-10 reverse stock split, now set for July 24, 2026.

Apimeds Pharmaceuticals US, Inc. announced the appointment of Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026.

Apimeds Pharmaceuticals US, Inc. has entered into a settlement and mutual release agreement to resolve outstanding disputes, restructure its operations, and establish new governance for its subsidiaries.

Apimeds Pharmaceuticals has received a notice of non-compliance from the NYSE American due to the delayed filing of its 2025 Annual Report.

Apimeds Pharmaceuticals US, Inc. announced a delay in filing its 2025 Annual Report on Form 10-K, citing ongoing audit procedures.

Apimeds Pharmaceuticals US, Inc. reported a significantly wider net loss in Q3 2025 as it ramped up research and development activities following its $11.9 million IPO, despite ongoing internal control weaknesses.

Apimeds Pharmaceuticals US, Inc. reported significantly increased net losses for Q2 2025 despite completing its initial public offering, alongside disclosing material weaknesses in internal financial controls.

Apimeds Pharmaceuticals US, Inc. reports a net loss for Q1 2025, but highlights the completion of its IPO and subsequent conversion of related party debt.

Apimeds Pharmaceuticals US, Inc. announced the completion of its merger with MindWave Innovations Inc., integrating a digital asset treasury platform alongside its biopharmaceutical business.

Apimeds Pharmaceuticals US, Inc. files an amendment to its annual report to disclose that its disclosure controls and procedures were not effective as of December 31, 2024, due to material weaknesses in internal controls over financial reporting.

Apimeds Pharmaceuticals US, Inc. outlines its capital stock, voting rights, and regulatory environment in its annual report, emphasizing its focus on developing Apitox for osteoarthritis and multiple sclerosis.

Apimeds Pharmaceuticals US, Inc. filed an amendment to its 8-K report to declare previous actions by majority stockholders, including director and officer removals, null and void due to contractual violations.

Apimeds Pharmaceuticals US, Inc. has completed a merger with MindWave Innovations Inc., combining its biopharmaceutical pipeline with MindWave's AI-driven Bitcoin treasury and digital asset yield generation, supported by a private investment of up to $120.9 million.

Inscobee Inc. filed an amended Form 4 to clarify its direct and indirect beneficial ownership of Apimeds Pharmaceuticals US, Inc. common stock.

Apimeds Pharmaceuticals US, Inc. Director Bennett Weintraub was granted options to purchase 10,000 shares of common stock at an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Hankil Yoon was granted 10,000 stock options with an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. director Jakap Koo was granted 10,000 stock options with an exercise price of $2.67, vesting over three years.

Apimeds Pharmaceuticals US, Inc. has completed a reverse merger with MindWave Innovations Inc., shifting its strategic focus to institutional digital asset treasury solutions while retaining its biopharmaceutical pipeline.

Apimeds Pharmaceuticals US, Inc. is moving forward with its initial public offering, as indicated by the filing of Amendment No. 7 to its Form S-1 registration statement.

Apimeds Pharmaceuticals US, Inc. files for an initial public offering aiming to raise $16.1 million to fund clinical trials for its bee venom-based therapy, Apitox, targeting osteoarthritis and multiple sclerosis.

Apimeds Pharmaceuticals US, Inc. is seeking to list its common stock on the NYSE American through a $14.4 million initial public offering.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its S-1 registration statement, indicating progress towards its initial public offering and plans to list on the NYSE American under the symbol APUS.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its S-1 registration statement for a firm commitment initial public offering of common stock, aiming to raise capital for clinical trials and operations.

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its registration statement for an initial public offering of its common stock, aiming to raise capital for clinical trials and operations.

Inscobee Inc. and Apimeds Inc. file Amendment No. 4 to Schedule 13D, detailing a settlement agreement resolving disputes and granting an irrevocable proxy.

Major holders led by Inscobee and Apimeds Inc. removed directors and executives at Apimeds Pharmaceuticals US via written consent, rejecting MindWave’s legal challenge.

Majority shareholders of Apimeds Pharmaceuticals US, Inc. have removed the entire board and appointed new directors following concerns over a recent merger and digital asset ownership.

Major shareholders of Apimeds Pharmaceuticals US, Inc. are challenging the validity of a recent merger with MindWave Innovations Inc., alleging potential wrongdoing by the board and management.

Inscobee Inc. and its subsidiary Apimeds Inc. have jointly disclosed a combined beneficial ownership of 55.4% in Apimeds Pharmaceuticals US, Inc. following the company's initial public offering and the conversion of outstanding promissory notes.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 9.99% beneficial ownership stake in Apimeds Pharmaceuticals US, Inc. through convertible notes.